Amivantamab just nearly DOUBLED response rates in head & neck cancer that had already failed immunotherapy + chemo. OrigAMI-4 trial results: → ~45% objective response (vs ~10–24% historical) → 6.8mo median PFS → response in 6.6 weeks → low discontinuation The trick: blocking EGFR + MET at the same time. 🧵👇